Graves' disease is a common disease of the thyroid caused by autoimmunity and can produce serious complications including cardiac problems and eye disease. Environmental factors play some role, but development of disease is strongly conditioned by genetic factors including inheritance of specific HLA Class II genes, and a specific version of the CTLA-4 gene. We have previously investigated the role of Class II MHC genes in Graves' disease through their presentation of T cell epitopes derived from the TSH receptor on antigen presenting cells, to T cells, in the development of immunity. We have shown that certain TSH receptor epitopes, which frequently stimulate T cells from patients with Graves' disease, bind with moderate affinity to HLA-DRbetal*0301. We will study the interaction of TSH receptor epitopes, HLA proteins, and T cells to better understand the development of disease and methods for possible inhibition of the immune process. Binding of TSH receptor epitopes to all of the DR and DQ proteins commonly found in our Graves' patients will be detailed and related to the genotype of the patient and reactivity of T cells from patients with the same genotype. Using computer algorithms, affinity studies, and T cell responses, as well as information gained from sequencing eluted epitopes from DR protein, we will establish the important or immunodominant TSH receptor T cell epitopes. With this information in hand, we will attempt to derive mutated TSH receptor sequences which inhibit the response of patients' T cells to TSH receptor epitopes. We will also use TSH receptor epitopes bound in DR or DQ molecules, or in tetramers, to remove reactive T cells from patient blood samples in vitro to determine whether a method can be found to reduce immunoreactivity. In a model of Graves' disease in TSH-R-immunized mice, we will develop epitopes that may inhibit the disease process, including the development of ophthalmopathy. Such epitopes might similarly be used in patients in the future. Our studies will be done in collaboration with Dr. A. Godkin, who will analyze TSH-R epitopes in a computer algorithm, Dr. R .G. Phelps, who will analyze TSH-R epitopes which we elute from DR3 molecules, Dr. W. Kwok, who will provide DR3 tetramers, and with Dr. M. Ludgate on the model of Graves' disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK027384-24
Application #
6894696
Study Section
Endocrinology Study Section (END)
Program Officer
Spain, Lisa M
Project Start
1980-07-01
Project End
2008-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
24
Fiscal Year
2005
Total Cost
$341,000
Indirect Cost
Name
Brown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Inaba, Hidefumi; Moise, Leonard; Martin, William et al. (2013) Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides. Endocrinology 154:2234-43
Inaba, Hidefumi; Martin, William; Ardito, Matt et al. (2010) The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease. J Clin Endocrinol Metab 95:2909-16
De Groot, L J; Shin, Y Ha; Pan, D et al. (2009) Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves' disease. J Endocrinol Invest 32:52-6
Inaba, Hidefumi; Martin, William; De Groot, Anne S et al. (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. J Clin Endocrinol Metab 91:2286-94
Takara, Masaki; Kouki, Tsuyoshi; DeGroot, Leslie J (2003) CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves' disease. Thyroid 13:1083-9
Gardine, C A; Gentile, F; Pellegrini, C et al. (2003) Multiple fragments of human TG are capable of inducing oral tolerance to whole human TG. J Endocrinol Invest 26:294-300
Kouki, T; Gardine, C A; Yanagawa, T et al. (2002) Relation of three polymorphisms of the CTLA-4 gene in patients with Graves' disease. J Endocrinol Invest 25:208-13
Gardine, C A; Kouki, T; DeGroot, L (2001) Characterization of the T lymphocyte subsets and lymphoid populations involved in the induction of low-dose oral tolerance to human thyroglobulin. Cell Immunol 212:1-15
Kouki, T; Sawai, Y; Gardine, C A et al. (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606-11
White, D M; Takeda, T; DeGroot, L J et al. (1997) Beta-trace gene expression is regulated by a core promoter and a distal thyroid hormone response element. J Biol Chem 272:14387-93

Showing the most recent 10 out of 56 publications